St. Louis, MO, United States of America

Clifford Bellone

USPTO Granted Patents = 2 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2022-2023

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Clifford Bellone

Introduction

Clifford Bellone is an accomplished inventor based in St. Louis, MO. He has made significant contributions to the field of enzyme replacement therapy, particularly in the treatment of lysosomal storage disorders. With a total of 2 patents, his work has the potential to improve the lives of individuals suffering from mucopolysaccharidosis type IVA.

Latest Patents

One of Clifford Bellone's latest patents focuses on a method of treating mucopolysaccharidosis type IVA. This patent discloses methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy. Specifically, it highlights immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). The patent also outlines methods of inducing oral tolerance towards a target enzyme through the oral administration of these immunodominant peptides prior to commencing enzyme replacement therapy. This innovative approach aims to enhance the effectiveness of treatment for patients suffering from this condition.

Career Highlights

Clifford Bellone is affiliated with Saint Louis University, where he continues to advance his research and innovations. His work is characterized by a commitment to improving therapeutic strategies for lysosomal storage disorders. His contributions to the field have garnered attention and recognition from peers and the medical community.

Collaborations

Clifford collaborates with talented individuals such as Adriana M Montaño-Suarez and Angela Catalina Sosa-Molano. These collaborations enhance the research efforts and contribute to the development of effective treatments in the field.

Conclusion

Clifford Bellone's innovative work in enzyme replacement therapy represents a significant advancement in the treatment of mucopolysaccharidosis type IVA. His patents and research efforts are paving the way for improved therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…